Firebrick Pharma Limited (ASX:FRE – Get Free Report) insider Peter Molloy acquired 454,545 shares of the stock in a transaction dated Thursday, October 10th. The shares were purchased at an average price of A$0.06 ($0.04) per share, for a total transaction of A$24,999.98 ($16,778.51).
Firebrick Pharma Price Performance
About Firebrick Pharma
Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia. The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name. It also operates in the United states and Singapore.
Featured Stories
- Five stocks we like better than Firebrick Pharma
- Health Care Stocks Explained: Why You Might Want to Invest
- Goldman Sachs Earnings Reveal Market Moves Investors Can’t Ignore
- What Are the FAANG Stocks and Are They Good Investments?
- AMD Gains Momentum With AI: Can It Beat Expectations?
- Conference Calls and Individual Investors
- Lithium Grab: 2 Lithium Stocks That Could Be Takeover Targets
Receive News & Ratings for Firebrick Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Firebrick Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
